SEC Form 4 · accession 0001209191-18-035861
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sangeeta N. Bhatia
Director
Period of report
Jun 1, 2018
Accepted (ET)
Jun 5, 2018 · 5:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 1, 2018 | A | 1,801 | $0.00 | A | 5,754 | D | |
| Common Stock | Jun 4, 2018 | S | 875 | $152.05 | D | 4,879 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $152.74 | Jun 1, 2018 | A | 3,229 | A | — | May 31, 2028 | Common Stock | 3,229 | 3,229 | D |
Explanation of responses
- F1Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
- F2Transaction made pursuant to Dr. Bhatia's company-approved trading plan under Rule 10b5-1.
- F3Fully vested.